Search: onr:"swepub:oai:gup.ub.gu.se/50152" > A comparison of the...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04847naa a2200685 4500 | |
001 | oai:gup.ub.gu.se/50152 | |
003 | SwePub | |
008 | 240528s2006 | |||||||||||000 ||eng| | |
009 | oai:lup.lub.lu.se:9030a1ca-917d-4fc1-90aa-9dd8ba750dbb | |
024 | 7 | a https://gup.ub.gu.se/publication/501522 URI |
024 | 7 | a https://lup.lub.lu.se/record/6933482 URI |
024 | 7 | a https://doi.org/10.1016/j.jacc.2005.11.0692 DOI |
040 | a (SwePub)gud (SwePub)lu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Cleland, J. G.4 aut |
245 | 1 0 | a A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET) |
264 | 1 | b Elsevier BV,c 2006 |
520 | a OBJECTIVES: This study was designed to investigate the loss of well-being, in terms of life-years, overall and in patients randomized to metoprolol versus carvedilol in the Carvedilol Or Metoprolol European Trial (COMET). BACKGROUND: The ultimate objectives of treating patients with heart failure are to relieve suffering and prolong life. Although the effect of treatment on mortality is usually described in trials, the effects on patient well-being throughout the trials' courses are rarely reported. METHODS: A total of 3,029 patients randomized in the COMET study were included in the analysis. "Patient journey" was calculated by adjusting days alive and out of hospital over four years using a five-point score completed by the patient every four months, adjusted according to the need for intensification of diuretic therapy. Scores ranged from 0% (dead or hospitalized) to 100% (feeling very well). RESULTS: Over 48 months, 17% of all days were lost through death, 1% through hospitalization, 23% through impaired well-being, and 2% through the need for intensified therapy. Compared with metoprolol, carvedilol was associated with fewer days lost to death, with no increase in days lost due to impaired well-being or days in hospital. The "patient journey" score improved from a mean of 54.8% (SD 26.0) to 57.4% (SD 26.3%) (p < 0.0068). CONCLUSIONS: Despite treatment with beta-blockers, heart failure remains associated with a marked reduction in well-being and survival. Loss of quality-adjusted life-years through death and poor well-being seemed of similar magnitude over four years, and both were much larger than the loss that could be attributed to hospitalization. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng |
653 | a Adrenergic beta-Antagonists/*therapeutic use | |
653 | a Aged | |
653 | a Carbazoles/*therapeutic use | |
653 | a Cardiac Output | |
653 | a Low/*drug therapy/mortality/*physiopathology/therapy | |
653 | a Chronic Disease | |
653 | a Diuretics/administration & dosage/therapeutic use | |
653 | a Dose-Response Relationship | |
653 | a Drug | |
653 | a Double-Blind Method | |
653 | a Female | |
653 | a Hospitalization | |
653 | a Humans | |
653 | a Male | |
653 | a Metoprolol/*therapeutic use | |
653 | a Middle Aged | |
653 | a Propanolamines/*therapeutic use | |
653 | a *Quality of Life | |
653 | a Severity of Illness Index | |
653 | a Treatment Outcome | |
700 | 1 | a Charlesworth, A.4 aut |
700 | 1 | a Lubsen, J.4 aut |
700 | 1 | a Swedberg, Karl,d 1944u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine4 aut0 (Swepub:gu)xsweka |
700 | 1 | a Remme, W. J.4 aut |
700 | 1 | a Erhardt, Leif RWu Lund University,Lunds universitet,Internmedicin - epidemiologi,Forskargrupper vid Lunds universitet,Internal Medicine - Epidemiology,Lund University Research Groups4 aut0 (Swepub:lu)medf-ler |
700 | 1 | a Di Lenarda, A.4 aut |
700 | 1 | a Komajda, M.4 aut |
700 | 1 | a Metra, M.4 aut |
700 | 1 | a Torp-Pedersen, C.4 aut |
700 | 1 | a Poole-Wilson, P. A.4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin4 org |
773 | 0 | t Journal of the American College of Cardiologyd : Elsevier BVg 47:8, s. 1603-11q 47:8<1603-11x 1558-3597x 0735-1097 |
856 | 4 | u http://dx.doi.org/10.1016/j.jacc.2005.11.069y FULLTEXT |
856 | 4 | u https://doi.org/10.1016/j.jacc.2005.11.069 |
856 | 4 8 | u https://gup.ub.gu.se/publication/50152 |
856 | 4 8 | u https://lup.lub.lu.se/record/693348 |
856 | 4 8 | u https://doi.org/10.1016/j.jacc.2005.11.069 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.